V#PHTwitJC will discuss the following paper on Sunday 18th December
M Jit et al (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom British Medical Journal, 337:a769
Why is this area of public health important?
- Human papillomaviruses (HPV) are responsible for nearly 3000 cases of cervical cancer and more than 100,000 diagnosed cases of anogenital warts in the United Kingdom every year
- HPV vaccination could decrease the incidence (new cases) of cervical and other cancers and anogenital warts.
How does this study add to our knowledge?
- This study assessed the cost effectiveness of routine vaccination of 12 year old schoolgirls against HPV infection in the United Kingdom.
- It found that routine vaccination of girls aged 12 combined with an initial catch-up campaign up to age 18 is likely to be cost effective.
- Vaccination of boys is unlikely to be cost effective.
- A vaccine against HPV types 16 and 18 costing £13-£21 less per dose (depending on duration of vaccine protection) would be as cost effective as a vaccine against virus types 6, 11, 16, and 18
Discussion Points for Sunday 18th December @ 8pm:
- Were the aims of this study clear?
- Were the parameters used in the economic model clear, relevant and valid?
- Are the findings justifiable considering the information inputted into the models?
- Could anything else explain the results (chance, bias, confounders?)
- What implications do the findings have for public health practice & policy?